Amylin Announces New Clinical Data From EUREXA Study - Quick Facts

6/9/2012 8:53 AM ET

Amylin Pharmaceuticals, Inc. (AMLN: Quote) announced new clinical data from the European Exenatide or EUREXA study that showed treatment with BYETTA injection resulted in greater glycemic durability and overall glycemic control than Amaryl in patients with type 2 diabetes uncontrolled on metformin alone.

The company also noted that patients treated with BYETTA have experienced reductions in body weight and fewer hypoglycemic events.

The company said these clinical study findings are being presented at the 2012 ADA/The Lancet Symposium at the 72nd Scientific Sessions of the American Diabetes Association in Philadelphia and will be published in the diabetes-themed issue of The Lancet.

Click here to receive FREE breaking news email alerts for Amylin Pharmaceuticals Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 140 Articles Next>>

Editors Pick

Red Hat Results Edge Past Estimates

Red Hat Inc., the world's largest seller of Linux software, said Wednesday after the markets closed that its first quarter profit rose 8% from last year, as revenue increased 15% amid strong consumer demand. The company's quarterly earnings per share, excluding items, also came in above analysts' expectations as did its quarterly revenue.

Negative Reaction To Fed Leads To Sell-Off On Wall Street - U.S. Commentary

After moving mostly higher over the course of the two previous sessions, stocks pulled back sharply during trading on Wednesday. A negative reaction to the Federal Reserve's monetary policy announcement weighed on the markets in afternoon trading. The major averages saw some volatility following the announcement from the Fed, closing firmly in the red.

CBO Finds Senate Immigration Bill Would Reduce Budget Deficit

Providing a potential boost to comprehensive immigration reform, the non-partisan Congressional Budget Office has estimated that the immigration bill currently being debated in the Senate would result in a notable reduction to the federal budget deficit.